Pegylated liposomal doxorubicin (Lipo-Dox®) for platinum-resistant or refractory epithelial ovarian carcinoma: A Taiwanese gynecologic oncology group study with long-term follow-up

Salvage Chemotherapy in Recurrent Platinum-Resistant or Refractory Epithelial Ovarian Cancer with Carboplatin and Distearoylphosphatidylcholine Pegylated Liposomal Doxorubicin (Lipo-Dox®)

“…Although recently, there is a multi-institutional phase II trial regarding combination of PLD to another agent such as panitumumab, the first fully human monoclonal antibody specific to EGF receptor in platinum resistant/ refractory ovarian cancer patients, the progression free and overall survival are still not apparently superior comparing the combination of PLD with carboplatin (Steffensen et al, 2013). According to our study, we found the overall response rate was 23.07% which was similar to previous Taiwanese study (Chou et al, 2006). With a median follow-up of 27.4 months, the median progression-free and median overall survivals in the 36 patients was 4.46 months and 8.76 months respectively which were rather shorter than previous study.…”

“…Chou et al studied second-generation PLD drug, Lipo-Dox ® with a dose of 45 mg/m 2 at a 4-week interval in 26 heavily pretreated resistant or refractory ovarian cancers patients and found the response rate of 23.1% with median progression-free interval and median overall survival time of 5.4 months and 13.8 months, respectively. They found that Lipo-Dox ® provided a response rate comparable with that of Doxil on similar patients (Chou et al, 2006). In our study ,we prescribed Lipo-Dox ® , combined with carboplatin which was reported in a number of studies to have synergistic combination and found superior with regard to progression free survival and also safety profile (du Bois et al, 2007;Ferrero 2007;Alberts et al, 2008;Power et al, 2009;Strother and Matei, 2009;Grenader et al, 2012).…”

“…Grade1/2 stomatitis and pharyngitis were observed in 28.4% of all cycles. Their patients showed less hand-foot syndrome, but more stomatitis and pharyngitis (Chou et al, 2006). According to our study, we found that the most common toxicity was leucopenia which occurred in 66.7%.…”

“…Lipo-Dox ® (DPLD), (TTY BioPharm, Taipei, Taiwan) is a second-generation PLD drug containing distearoylphosphatidylcholine that has been commercially available in Taiwan since 1998 (Yuda et al, 1996;Hong, 2001). A Taiwanese gynecologic oncology group has reported, in a multicenter phase II trial, that single agent DPLD at 45 mg/m 2 every 4 weeks is effective against recurrent, platinum resistant epithelial ovarian cancer (Chou et al, 2006). The objective of this study is to evaluate the efficacy and safety of a distearoylphosphatidylcholine pegylated liposomal doxorubicin (DPLD) combined with carboplatin in the treatment of platinum-resistant or refractory epithelial ovarian cancer in Thai patients treated at King Chulalongkorn Memorial hospital ,Thailand.…”

Lipossomas e suas aplicações terapêuticas: estado da arte

“…Portanto, são pequenos o suficiente para extravasar do sangue para o espaço intersticial do tumor passando através desses poros (Lasic, 1998;Sapra, Allen, 2003). Chou et al (2006) avaliaram a atividade da doxorrubicina encapsulada em lipossomas furtivos (LipoDox ® ) em pacientes com carcinoma ovariano epitelial resistente à platina na dose de 45 mg/m 2 a cada quatro semanas. A eficácia do Lipo-Dox foi constatada em câncer recorrente e platina-resistente.…”